Search
Influenza vaccination of children with medical comorbidities is critical due their increased risks for severe influenza disease. In Australia, hospitals are an avenue for influenza vaccine delivery to children with comorbidities but are not always effectively utilised. Qualitative enquiry sought to ascertainment the barriers and enablers for influenza vaccination recommendation, delivery, and recording of these children at Australian hospitals.
Current immunization guidelines recommend one dose of influenza vaccine for children aged ≥9 years and two doses for younger or vaccine-naïve children. However, children receiving chemotherapy have an attenuated immune response. We performed a prospective open-label study in children undergoing treatment for cancer at Perth Children's Hospital, Western Australia, to examine the safety and efficacy of a boosted influenza schedule.
Active vaccine safety surveillance leading to rapid detection of a safety signal would likely have resulted in earlier suspension of Fluvax from the vaccination programme
This report summarises the epidemiology of hospitalisations with laboratory-confirmed influenza during the 2017 influenza season
Improving parents’ and providers’ knowledge and confidence in influenza vaccination safety, efficacy, and benefits should be prioritised
Overall, the 2016 influenza vaccine showed good protection against laboratory-confirmed infection among general practice patients
This large population-based study suggests a significant healthcare burden associated with influenza in children with a range of chronic lung diseases
Influenza infection in young children has a significant impact on medication use, absenteeism and the use of health care service
These baseline data are essential to assess the safety and effectiveness of influenza and pertussis vaccinations in pregnant women from the NT
AusVaxSafety surveillance demonstrated comparable and expected safety outcomes for the 2017 quadrivalent inactivated influenza vaccine brands used in Australia